AQW051

DRUG6 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

Amnestic Mild Cognitive ImpairmentDrug-inducedDyskinesiasHealthyMild Alzheimer's DiseaseSchizophrenia

Phase 1

Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects

CompletedNCT00409500

NovartisHealthy

Start: 2006-10-31Target: 54Updated: 2007-06-22

Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.

CompletedNCT00418002

NovartisHealthy

Start: 2006-05-31Target: 72Updated: 2007-06-22

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

CompletedNCT00825539

Novartis PharmaceuticalsSchizophrenia

Start: 2009-01-31End: 2011-11-30Updated: 2020-12-24

Phase 2

Effect of AQW051 in Patients With Memory Impairment

TerminatedNCT00582855

Novartis PharmaceuticalsAmnestic Mild Cognitive Impairment, Mild Alzheimer's Disease

Start: 2007-12-31Updated: 2016-04-19

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

CompletedNCT01474421

Novartis PharmaceuticalsDrug-induced, Dyskinesias

Start: 2011-09-15End: 2013-02-21Updated: 2020-12-24

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

CompletedNCT01730768

Novartis PharmaceuticalsSchizophrenia

Start: 2012-09-30End: 2013-12-31Updated: 2020-12-24

Related Papers

Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.

2016-06-289 citations